2000
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
Johnson K, Brooks B, Ford C, Goodman A, Guarnaccia J, Lisak R, Myers L, Panitch H, Pruitt A, Rose J, Kachuck N, Wolinsky J. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Multiple Sclerosis Journal 2000, 6: 255-266. PMID: 10962546, DOI: 10.1177/135245850000600407.Peer-Reviewed Original ResearchConceptsExpanded Disability Status ScaleOpen-label phaseOpen-label studyAccumulation of disabilityDaily subcutaneous injectionsGlatiramer acetateRelapse rateMultiple sclerosisSubcutaneous injectionRelapsing-remitting multiple sclerosisMean annual relapse rateDouble-blind cohortDouble-blind phaseSustained clinical benefitDouble-blind studyDisability Status ScaleAnnual relapse rateMultiple sclerosis patientsSclerosis patientsClinical benefitStatus ScaleSustained efficacyPatientsActive drugGlatiramer
1997
Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis
Cook S, Devereux C, Troiano R, Wolansky L, Guarnaccia J, Haffty B, Bansil S, Goldstein J, Sheffet A, Zito G, Jotkowitz A, Boos J, Dowling P, Rohowsky-Kochan C, Volmer T. Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis. Journal Of The Neurological Sciences 1997, 152: 172-181. PMID: 9415539, DOI: 10.1016/s0022-510x(97)00189-5.Peer-Reviewed Original ResearchConceptsTotal lymphoid irradiationMultiple sclerosisLymphoid irradiationDuration of MSExpanded Disability Status ScaleProgressive formKaplan-Meier product-limit survival analysisLow-dose corticosteroidsLow-dose prednisoneProgressive multiple sclerosisPrimary study endpointDisability Status ScaleProduct-limit survival analysisDose corticosteroidsDose prednisoneIntravenous methylprednisolonePrednisone therapyTLI groupTLI patientsSystemic immunosuppressionPatient ageStudy endpointStudy entrySham groupStatus Scale